company background image
VERU

Veru NasdaqCM:VERU Stock Report

Last Price

US$5.68

Market Cap

US$455.2m

7D

3.1%

1Y

-17.8%

Updated

30 Nov, 2022

Data

Company Financials +
VERU fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VERU Stock Overview

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of breast and prostate cancers.

Veru Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Veru
Historical stock prices
Current Share PriceUS$5.68
52 Week HighUS$24.55
52 Week LowUS$4.34
Beta-0.20
1 Month Change-53.60%
3 Month Change-62.88%
1 Year Change-17.80%
3 Year Change159.36%
5 Year Change462.38%
Change since IPO-14.26%

Recent News & Updates

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Oct 17

Recent updates

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Sep 26
Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Is Veru (NASDAQ:VERU) Using Debt Sensibly?

May 25
Is Veru (NASDAQ:VERU) Using Debt Sensibly?

Newsflash: Veru Inc. (NASDAQ:VERU) Analysts Have Been Trimming Their Revenue Forecasts

Feb 11
Newsflash: Veru Inc. (NASDAQ:VERU) Analysts Have Been Trimming Their Revenue Forecasts

Health Check: How Prudently Does Veru (NASDAQ:VERU) Use Debt?

Nov 15
Health Check: How Prudently Does Veru (NASDAQ:VERU) Use Debt?

We Take A Look At Whether Veru Inc.'s (NASDAQ:VERU) CEO May Be Underpaid

Mar 17
We Take A Look At Whether Veru Inc.'s (NASDAQ:VERU) CEO May Be Underpaid

Shareholders In Veru (NASDAQ:VERU) Should Look Beyond Earnings For The Full Story

Feb 23
Shareholders In Veru (NASDAQ:VERU) Should Look Beyond Earnings For The Full Story

News Flash: Analysts Just Made An Incredible Upgrade To Their Veru Inc. (NASDAQ:VERU) Forecasts

Feb 17
News Flash: Analysts Just Made An Incredible Upgrade To Their Veru Inc. (NASDAQ:VERU) Forecasts

Here's Why Veru (NASDAQ:VERU) Can Manage Its Debt Responsibly

Feb 16
Here's Why Veru (NASDAQ:VERU) Can Manage Its Debt Responsibly

If You Had Bought Veru (NASDAQ:VERU) Stock Three Years Ago, You Could Pocket A 617% Gain Today

Jan 27
If You Had Bought Veru (NASDAQ:VERU) Stock Three Years Ago, You Could Pocket A 617% Gain Today

Breakeven On The Horizon For Veru Inc. (NASDAQ:VERU)

Jan 05
Breakeven On The Horizon For Veru Inc. (NASDAQ:VERU)

What Kind Of Investors Own Most Of Veru Inc. (NASDAQ:VERU)?

Dec 15
What Kind Of Investors Own Most Of Veru Inc. (NASDAQ:VERU)?

Shareholder Returns

VERUUS Personal ProductsUS Market
7D3.1%-2.3%-0.9%
1Y-17.8%-38.1%-18.9%

Return vs Industry: VERU exceeded the US Personal Products industry which returned -38.9% over the past year.

Return vs Market: VERU underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is VERU's price volatile compared to industry and market?
VERU volatility
VERU Average Weekly Movement23.7%
Personal Products Industry Average Movement10.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: VERU's weekly volatility has decreased from 33% to 24% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1971252Mitch Steinerhttps://www.verupharma.com

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company’s drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral cytoskeleton disruptor plus selective androgen receptor agonist that is in phase 2b clinical trial for the treatment of metastatic triple negative breast cancer.

Veru Inc. Fundamentals Summary

How do Veru's earnings and revenue compare to its market cap?
VERU fundamental statistics
Market CapUS$455.23m
Earnings (TTM)-US$47.05m
Revenue (TTM)US$52.41m

8.7x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VERU income statement (TTM)
RevenueUS$52.41m
Cost of RevenueUS$10.02m
Gross ProfitUS$42.40m
Other ExpensesUS$89.44m
Earnings-US$47.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Dec 05, 2022

Earnings per share (EPS)-0.59
Gross Margin80.89%
Net Profit Margin-89.77%
Debt/Equity Ratio12.5%

How did VERU perform over the long term?

See historical performance and comparison